Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 14;13(3):783.
doi: 10.3390/life13030783.

Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023

Marta Bassi  1   2 , Daniele Franzone  2 , Francesca Dufour  2 , Marina Francesca Strati  2 , Marta Scalas  2 , Giacomo Tantari  1   2 , Concetta Aloi  3 , Alessandro Salina  3 , Giuseppe d'Annunzio  1 , Mohamad Maghnie  1   2 , Nicola Minuto  1
Affiliations
Review

Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023

Marta Bassi et al. Life (Basel). .

Abstract

Type 1 diabetes (T1D) patients' lifestyle and prognosis has remarkably changed over the years, especially after the introduction of insulin pumps, in particular advanced hybrid closed loop systems (AHCL). Emerging data in literature continuously confirm the improvement of glycemic control thanks to the technological evolution taking place in this disease. As stated in previous literature, T1D patients are seen to be more satisfied thanks to the use of these devices that ameliorate not only their health but their daily life routine as well. Limited findings regarding the use of new devices in different age groups and types of patients is their major limit. This review aims to highlight the main characteristics of each Automated Insulin Delivery (AID) system available for patients affected by Type 1 Diabetes Mellitus. Our main goal was to particularly focus on these systems' efficacy and use in different age groups and populations (i.e., children, pregnant women). Recent studies are emerging that demonstrate their efficacy and safety in younger patients and other forms of diabetes.

Keywords: AHCL (advanced hybrid closed loop); AID (automated insulin delivery); APS (artificial pancreas systems); CGM (continuous glucose monitoring); CSII (continuous subcutaneous insulin infusion); insulin pumps; type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
History of the evolution of technology for the treatment of type 1 diabetes.
See this image and copyright information in PMC

References

    1. Boughton C.K., Hovorka R. New closed-loop insulin systems. Diabetologia. 2021;64:1007–1015. doi: 10.1007/s00125-021-05391-w. - DOI - PMC - PubMed
    1. Leelarathna L., Choudhary P., Wilmot E.G., Lumb A., Street T., Kar P., Ng S.M. Hybrid closed-loop therapy: Where are we in 2021? Diabetes, Obes. Metab. 2020;23:655–660. doi: 10.1111/dom.14273. - DOI - PubMed
    1. Ware J., Hovorka R. Closed-loop insulin delivery: Update on the state of the field and emerging technologies. Expert Rev. Med. Devices. 2022;19:859–875. doi: 10.1080/17434440.2022.2142556. - DOI - PMC - PubMed
    1. Bergenstal R.M., Tamborlane W.V., Ahmann A., Buse J.B., Dailey G., Davis S.N., Joyce C., Peoples T., Perkins B.A., Welsh J.B., et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. N. Engl. J. Med. 2010;363:311–320. doi: 10.1056/NEJMoa1002853. - DOI - PubMed
    1. Bergenstal R.M., Klonoff D.C., Garg S.K., Bode B.W., Meredith M., Slover R.H., Ahmann A.J., Welsh J.B., Lee S.W., Kaufman F.R. Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia. N. Engl. J. Med. 2013;369:224–232. doi: 10.1056/NEJMoa1303576. - DOI - PubMed